The US Food and Drug Administration on Friday approved Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed genetically-modified autologous T-cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma.
Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma, the agency pointed out.
News of the approval saw shares of the product’s developers - US pharma major Bristol Myers Squibb (NYSE: BMY) and biotech firm bluebird bio (Nasdaq: BLUE) - edge up 1.8% and 1.2%, respectively, and also marks a significant milestone for BMS, making the latter the only company with two approved CAR-T cell therapies with two distinct targets; last month Breyanzi (lisocabtagene maraleucel; liso-cell) was approved by the FDA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze